Lito Sousa receives experimental treatment, AI video sparks debate

Lito Sousa has once again made headlines by publishing a video identified as artificial intelligence content and by starting experimental treatment for Creutzfeldt-Jakob disease. The publication sparked curiosity and divided followers' opinions.

AI Video Divides Followers

In the content, Lito appears asking who attended "Domingo Aéreo 2026" (Air Sunday 2026), using a characteristic tone. Some followers questioned the veracity of the content, while others praised the technology's creativity.

Use of Experimental Medication

Since September, Lito has been receiving the substance ALN-6457, exceptionally imported by Anvisa to treat Creutzfeldt-Jakob. The drug, still in its preclinical phase, has not yet demonstrated proven efficacy.

First Brazilian Patient

The treatment is taking place at the Hospital Israelita Albert Einstein in São Paulo, following authorization for individual use. Lito is the first human to receive the substance produced by Regeneron Pharmaceuticals in the country.

Wife Debunks Rumors of Improvement

Mila Seidl, Lito's wife, used social media to deny false reports of recovery. She stated that, to date, there has been no improvement and the situation remains complicated.

Social Media Repercussion

The video generated questions like "Is this video current?" and "Why do this?", revealing that part of the public did not realize the use of AI. Other comments celebrated the initiative as a loving way to remember the influencer.

Treatment Context

Creutzfeldt-Jakob is a neurodegenerative disease with no known cure, with a high mortality rate within a few months after the onset of symptoms. Ministry of Health literature indicates that approximately 90% of patients die between six months and one year.

With information from UOL, Correio Braziliense.